Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
2
Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis
3
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
4
Patient-Centered Treatment Transitions in HR+/HER2− mBC
5